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ABSTRACT: Plasma-free metanephrines and catecholamines are essential
markers in the biochemical diagnosis and follow-up of neuroendocrine tumors
and inborn errors of metabolism. However, their low circulating concentrations
(in the nanomolar range) and poor fragmentation characteristics hinder facile
simultaneous quantification by liquid chromatography and tandem mass
spectrometry (LC-MS/MS). Here, we present a sensitive and simple matrix
derivatization procedure using propionic anhydride that enables simultaneous
quantification of unconjugated L-DOPA, catecholamines, and metanephrines in
plasma by LC-MS/MS. Dilution of propionic anhydride 1:4 (v/v) in acetonitrile
in combination with 50 μL of plasma resulted in the highest mass spectrometric
response. In plasma, derivatization resulted in stable derivatives and increased
sensitivity by a factor of 4−30 compared with a previous LC-MS/MS method for
measuring plasma metanephrines in our laboratory. Furthermore, propionylation
increased specificity, especially for 3-methoxytyramine, by preventing interference
from antihypertensive medication (β-blockers). The method was validated according to international guidelines and correlated with
a hydrophilic interaction LC-MS/MS method for measuring plasma metanephrines (R2 > 0.99) and high-performance liquid
chromatography with an electrochemical detection method for measuring plasma catecholamines (R2 > 0.85). Reference intervals for
L-DOPA, catecholamines, and metanephrines in n = 115 healthy individuals were established. Our work shows that analytes in the
subnanomolar range in plasma can be derivatized in situ without any preceding sample extraction. The developed method shows
improved sensitivity and selectivity over existing methods and enables simultaneous quantification of several classes of amines.
Plasma catecholamines including L-DOPA, epinephrine,norepinephrine, dopamine, and their metabolites the
metanephrines, which comprise metanephrine, normetanephr-
ine, and 3-methoxytyramine, are important diagnostic markers
(Figure S-1). Plasma-free metanephrines and catecholamines
are quantified for the diagnosis of catecholamine-producing
tumors like pheochromocytoma, paraganglioma, and neuro-
blastoma as well as inborn errors of monoamine neuro-
transmitter synthesis, metabolism, and transport.1−4
Simultaneous analysis of metanephrines and catecholamines
remains an analytical challenge because of their low
concentrations in plasma, the oxidation-prone catechol moiety,
potential chromatographic interferences, and poor fragmenta-
tion characteristics in the mass spectrometer.5,6 Several
analytical methods have been described to measure meta-
nephrines or catecholamines in plasma, including immuno-
assays, high-performance liquid chromatography (HPLC) with
electrochemical detection (ECD), gas chromatography
coupled with mass spectrometry, and liquid chromatography
with tandem mass spectrometry (LC-MS/MS).7−10 However,
most of these described methods are laborious, relatively
imprecise, and use large sample volumes.6,8 There is only one
method to date that describes the simultaneous analysis of
plasma metanephrines and catecholamines by LC-MS/MS.11
However, this method involves an offline extraction and
evaporation step, which can be delicate with oxidation-
sensitive catecholamines, and still needs 200 μL of plasma,
which is not ideal for volume-limited studies, such as those
using samples from a biobank or preclinical studies using
samples from animals. In addition, the catecholamine
precursor L-DOPA is not analyzed as it is not extracted by
the weak cation exchange sorbent employed in this method.
To improve the sensitivity of mass spectrometric detection of
catecholamines, several derivatization strategies have been
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proposed. However, these are time consuming and use toxic
chemicals which cannot easily be used in a clinical
laboratory.12,13 We have previously shown that in situ or
direct-matrix derivatization can be performed directly in
plasma without any preceding sample cleanup, improving
chemical stability during sample preparation.14 Other possible
advantages of derivatization are higher sensitivity by improved
ionization efficiency, improved fragmentation characteristics,
and more uniform and reproducible extraction and chromato-
graphic properties.
In this study, we describe the development and validation of
an automated LC-MS/MS method using direct-matrix
derivatization for the simultaneous quantification of free
fractions of L-DOPA, catecholamines, and metanephrines in
plasma at the picomolar level.
■ MATERIALS AND METHODS
Reagents. LC-MS grade acetonitrile, isopropanol, meth-
anol, formic acid, and ammonium acetate were purchased from
Biosolve BV (Valkenswaard, The Netherlands). Glutathione
(reduced), ascorbic acid, dipotassium hydrogen phosphate,
pyridine, and hydrochloric acid (32%) were from Merck
Millipore (Darmstadt, Germany). Ammonium hydroxide
solution (28−30%), propionic anhydride, K2EDTA dihydrate,
L-DOPA, dopamine-HCl, norepinephrine, epinephrine, 3-
methoxytyramine, DL-metanephrine-HCl, DL-normetanephr-
ine-HCl, and L-DOPA-d3, all of analytical purity, were
purchased from Sigma-Aldrich (MI, USA). Stable deuterated
isotopes for dopamine-d4-HCl, norepinephrine-d6-HCl, and
epinephrine-d3 were from CDN Isotopes (Pointe-Claire,
Canada), 3-methoxytyramine-d4-HCl and DL-metanephrine-
d3-HCl from Cambridge Isotopes (MA, USA), and DL-
normetanephrine-d3-HCl from Medical Isotopes (NH, USA).
Ultrapure water was produced using an in-house purification
system (Merck Millipore, MA, USA).
Preparation of Stock Solutions, Calibrators, and
Internal Standard Solutions. Stock solutions were prepared
in 0.08 mol/L acetic acid. Stock solutions were serially diluted
in ascorbic acid in water 0.04% (w/v) to their respective
working solutions (mix of all analytes). Stock solutions were
kept at −80 °C. Working solutions were prepared fresh on the
day of analysis to prevent degradation due to oxidation. Eight
calibrators were prepared by adding different volumes of
working solution into a surrogate matrix (dialyzed plasma; for
detailed description, see Supporting Information, section
Dialyzed plasma). Calibration curves ranged from 6.8 to 680
nmol/L (L-DOPA), from 0.070 to 7.0 nmol/L (dopamine),
from 0.31 to 31 nmol/L (norepinephrine), from 0.091 to 9.1
nmol/L (epinephrine), from 0.066 to 6.6 nmol/L (3-
methoxytyramine), from 0.26 to 26 nmol/L (normetanephr-
ine), and from 0.10 to 10 nmol/L (metanephrine). An internal
standard working solution was prepared in ascorbic acid in
water 0.04% (w/v) containing L-DOPA-d3 (270 nmol/L),
dopamine-d4 (1.7 nmol/L), norepinephrine-d6 (3.5 nmol/L),
epinephrine-d3 (2 nmol/L), 3-methoxytyramine-d4 (0.7 nmol/
L), normetanephrine-d3 (1.2 nmol/L), and metanephrine-d3
(0.7 nmol/L).
Optimization of the Derivatization Reaction. The
volume of plasma (50 and 100 μL) and the ratio of propionic
anhydride to acetonitrile (v/v) were optimized. The ratio of
propionic anhydride to acetonitrile was varied between an
undiluted, 1:1, 1:4, and 1:10 dilution in acetonitrile (v/v %).
Other experimental conditions, like buffer strength, buffer pH,
and incubation time, were as previously described.14 The
optimal incubation time for derivatization of the catechol-
amines and metanephrines was verified to be 15 min (Figure S-
3).14 The experiment was performed with six different plasma
pools obtained from anonymous patient samples that were
screened for plasma metanephrines at our laboratory. The
internal standard peak area was used to evaluate which
combination of variables gave the highest signal. The
derivatization procedure was performed as described below.
Derivatization Procedure. Aliquots of thawed plasma
samples (50 μL) and calibrators were mixed with 50 μL of
internal standard working solution, 250 μL of 0.5 mol/L
dipotassium phosphate, and 4 mol/L K2EDTA, pH 8.5 in a 2.0
mL 96-deep well plate (Greiner Bio-One). Then 50 μL of 25%
(v/v) propionic anhydride in acetonitrile was added, and the
plate was vortexed for 15 min. Water was added to all wells to a
total volume of 0.5 mL. The plate was vortexed and
centrifuged for 30 min at 1500g. Then 100 μL of each
calibrator and sample was injected onto the online solid-phase
extraction (SPE) LC-MS/MS system.
Online SPE and LC-MS/MS. Online SPE and liquid
chromatography were performed with an automated system as
previously described (Symbiosis Pharma system, Spark Hol-
land, Emmen The Netherlands).15 The online SPE procedure
was carried out on 1 × 10 mm Oasis HLB 30 μm SPE
cartridges. For a detailed description of the online SPE
procedure, see the Supporting Information (section Online
SPE and LC-MS/MS, and scheme in Figure S-2).
Liquid chromatography was performed on a Luna Phenyl-
Hexyl 2.0 × 150 mm, 3 μm column (Phenomenex, Torrance,
CA), with a binary gradient system that consisted of 10 mM
ammonium acetate with 0.1% formic acid (mobile phase A)
and 0.1% formic acid in 100% acetonitrile (mobile phase B).
Initial conditions were 80:20 (v/v) mobile phase A:mobile
phase B at a flow rate of 0.3 mL/min followed by a linear
increase of mobile phase B to 60% over 8.25 min. Thereafter,
mobile phase B was increased to 80% over 15 s, where it was
kept constant for 1 min. The mobile phase was then returned
to the starting conditions and kept constant for a further 1.5
min, giving a total run time of 11.5 min.
All analytes were analyzed in positive electrospray ionization
mode on a triple-quadrupole mass spectrometer (Waters Xevo
TQ-MS). Mass spectrometer transitions and settings were
optimized by tuning the derivatives in the selective reaction
monitoring (SRM) (Table S-1). The following settings were
applied throughout: capillary voltage 0.5 kV, desolvation
temperature 600 °C, nitrogen desolvation gas flow 1000 L/h,
nitrogen cone gas flow 50 L/h, and argon collision gas flow
0.20 mL/min. Analytes were quantitated using the peak-area
response ratios of the quantifier transitions for the analyte and
the corresponding internal standard. Calculations were
performed with Targetlynx version 4.1 (Waters, Milford,
MA, USA).
Evaluation of Assay Performance. The method was
validated by evaluating imprecision, limit of quantification
(LOQ), linearity, carryover, recovery, and ion suppression and
by comparing with other methods.16 The stability of
derivatives was tested by analyzing 38 derivatized plasma
samples at T = 0 and after T = 72 h in the autosampler.
Detailed information on the procedures for method validation
are provided in the Supporting Information (section Method
validation).
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Quality control (QC) plasma samples containing low,
medium, and high levels of the respective analytes were
prepared (see Table 1 for concentrations) using pooled
anonymized human EDTA plasma collected during routine
patient care for plasma- free metanephrines. This was classified
as non-WMO research (Dutch law on Research Involving
Human Subjects Act) and received an exemption from the
Medical Ethical Committee of our hospital. QC samples were
stabilized with glutathione (∼5 mg/mL) and stored at −80°C
until analysis. Methods for norepinephrine and epinephrine
were compared with the routine HPLC-ECD method in our
laboratory in 58 patient plasma samples.17 Methods for 3-
methoxytyramine, normetanephrine, and metanephrine were
compared with a hydrophilic interaction chromatography
(HILIC) LC-MS/MS method in our laboratory in 40 patient
plasma samples.15 Certain antihypertensive medications are
known to interfere in the LC-MS/MS analysis of metanephr-
ines.18 Our HILIC LC-MS/MS method for measuring 3-
methoxytyramine suffered from analytical interference from the
β-blocker metoprolol, which had been taken by the patient. To
check for analytical interferences, we analyzed plasma samples
from a previous study in which blood was collected from
patients before and 1 month after the start of antihypertensive
medication (β-blockers, thiazide diuretics, and angiotensin-
converting enzyme inhibitors).19 3-O-Methyldopa was also
tested as it can interfere with the analysis of plasma 3-
methoxytyramine.5 3-O-Methyldopa is fragmented in-source,
resulting in 3-methoxytyramine, which produces the same
fragment ions.5
Reference Interval Study. A reference interval study was
performed by analyzing 115 plasma samples from apparently
healthy individuals who gave informed consent. Detailed
information on the inclusion criteria and blood sampling can
be found in the Supporting Information (section Reference
interval study). The study was approved by the medical ethics
committee of the University Medical Center Groningen
(Netherlands trial register number NTR5066).
Statistics. Method comparisons and autosampler stability
were calculated by passing and Bablok regression using cp-R,
an interface to R.20 Reference ranges were calculated by
parametric analysis for 3-methoxytyramine and metanephrine
and log-transformed parametric analysis for L-DOPA, dop-
amine, norepinephrine, epinephrine, 3-methoxytyramine, and
normetanephrine using Analyze-it (Analyze-it Software, Ltd.,
Leeds, UK). Results were expressed as mean ± standard
deviation or median [interquartile range] for normally
distributed and non-normally distributed data, respectively.
■ RESULTS AND DISCUSSION
Derivatization. Optimization of the derivatization con-
ditions showed that a 1:4 propionic anhydride dilution in
acetonitrile (v/v) gave the highest internal standard area
responses (Figure 1). Undiluted propionic anhydride and the
1:1 propionic anhydride dilution showed a lower response for
catecholamines and metanephrines (5−26%, Table S-2)
because the pH drops below pH 7 almost immediately after
propionic anhydride is added, which stops the reaction. The
pH falls below 7 approximately 10 min after a 1:4 or 1:10
propionic anhydride dilution is added, which allows the
reaction to continue for longer. This decrease in pH combined
with in situ derivatization facilitated protein precipitation. After
centrifugation, the supernatant could be injected directly. We
tested if the addition of acetonitrile without propionic
anhydride also caused proteins to precipitate, but it did not.
The pI or tertiary structure of certain proteins is modified by
propionylation (derivatization of lysine side chain, hydroxyl
groups, and N-terminal amine groups). This, together with the
drop in pH after derivatization, causes proteins to precipitate.
The plasma volume was set at 50 μL as this gave consistently
higher responses compared with 100 μL of plasma. This may
be related to suppressed ionization or incomplete derivatiza-
tion when 100 μL of plasma is used. A 1:4 ratio of propionic
anhydride together with 50 μL of plasma was chosen for the
remaining experiments. Addition of stable isotope-labeled
internal standards before derivatization is pivotal in correcting
for any difference in derivatization efficiency between samples.
One can argue that there could be differences in derivatization
efficiency at different concentrations. The concentration of the
internal standard is fixed, whereas the concentrations of the
endogenous analytes vary. However, the interassay imprecision
experiments showed no considerable increase in variation at
lower analyte concentrations compared with higher concen-
trations. For example, when looking at 3-methoxytyramine, the
interassay imprecision was 3.1% at 0.110 nmol/L, 3.6% at
0.326 nmol/L, and 2.4% at 3.1 nmol/L (Table 1). Figure 2
illustrates the derivatization reaction of dopamine with
propionic anhydride. Derivatization resulted in precursors at
the theoretically predicted m/z for L-DOPA, dopamine, and 3-
methoxytyramine (Figure 3). For norepinephrine, epinephrine,
normetanephrine, and metanephrine, the most intense













QC low 10.2 2.1 7.1
QC med 46.8 2.3 4.1
QC high 329 2.1 3.9
dopamine 0.011
QC low 0.095 6.9 5.7
QC med 0.451 2.2 3.5
QC high 3.33 1.8 3.5
norepinephrine 0.010
QC low 2.26 2.3 3.3
QC med 4.48 1.7 3.3
QC high 17.1 1.7 2.4
epinephrine 0.030
QC low 0.216 4.2 0.5
QC med 0.652 4.5 5.8




QC low 0.110 3.5 3.1
QC med 0.326 1.6 3.6
QC high 3.10 1.3 2.4
normetanephrine 0.050
QC low 0.534 5.2 3.2
QC med 1.68 3.1 3.1
QC high 12.1 2.5 2.6
metanephrine 0.040
QC low 0.220 7.1 5.9
QC med 0.667 3.3 3.4
QC high 4.80 3.6 3.0
aAbbreviations: LOQ, limit of quantification; QC, quality control
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precursor m/z was that without the derivatized β-hydroxyl
group (hydroxyl group on the side chain). This group was
easily lost by in-source fragmentation, which could be avoided
by adjusting the cone voltage (see norepinephrine example in
Figure S-5). The fragmentation patterns of formed derivatives
were comparable for all analytes (Figure 3). Dependent on the
applied collision energy, the propionyl groups can be lost,
resulting in high intensity, analyte-dependent product ions.
This is illustrated for dopamine in Figure S-6, which shows the
product ion spectrum at collision energies of 15 and 30 eV.
Propionylation was shown to be effective in aqueous medium
for gas chromatographic analysis of biogenic amines and
showed advantages over the more reactive fluorinated
reagents.21−23. However, in this study, we did not perform in
situ derivatization in plasma but only in neat solutions and with
pyridine as a catalyst.
Assay Performance. For all analytes, intraassay and
interassay coefficients of variation were <8.2% (Table 1).
Only one other study analyzed catecholamines and meta-
nephrines (but not L-DOPA) in one analysis, and the
imprecision observed in the present study for the respective
analytes was comparable to or better than 11. Mean recovery
of the added analytes was 97−101% for L-DOPA, 100−104%
for dopamine, 95−105% for norepinephrine, 98−100% for
epinephrine, 97−100% for 3-methoxytyramine, 97−99% for
normetanephrine, and 95−99% for metanephrine (Table S-3).
Carryover was <0.1% for each analyte, and no significant ion
suppression was observed.
In situ derivatization resulted in stable derivatives, with an
autosampler stability of at least 72 h (Figures S-6 and S-7).
The increase in stability after derivatization for the catechol-
amines is critical, as catecholamines are prone to oxidation due
to their vicinal phenolic OH groups.24 Quantification limits for
most analytes were in the lower picomolar range (Table 1),
which corresponds to 100−500 amol on column. The
derivatization procedure resulted in an unprecedented LOQ
for each analyte compared with those reported in the literature,
especially when the sample volume is considered. Compared
with the HILIC LC-MS/MS method we use for plasma
metanephrines, sensitivity increased 30 times for 3-methoxytyr-
amine, 5 times for normetanephrine, and 4 times for
metanephrine.15 When examining the analytes with the lowest
plasma concentrations, namely, epinephrine, dopamine, and 3-
methoxytyramine, two previous reports showed comparable
LOQs for epinephrine (0.03 and 0.05 nmol/L, respectively)
but used 5−10 times more plasma than our method does.13,25
Figure 1. Effect of different derivatization reaction conditions on the internal standard peak-area response for the three different catecholamines.
Internal standard peak area is shown on the y axis, and ratio of propionic anhydride to acetonitrile (v/v) is on the x axis. (A) Results for dopamine-
d4 for 50 and 100 μL of plasma. (B) Results for norepinephrine-d6 for 50 and 100 μL of plasma. (C) Results for epinephrine-d3 for 50 and 100 μL
of plasma. (D) Results for 3-methoxytyramine-d4 for 50 and 100 μL of plasma. (E) Results for normetanephrine-d3 for 50 and 100 μL of plasma.
(F) Results for metanephrine-d3 for 50 and 100 μL of plasma. Results for L-DOPA-d3 are shown in Figure S-4.
Figure 2. Derivatization reaction of dopamine with propionic anhydride. Formed derivative product is shown on the right side.
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Two prior reports on LC-MS/MS methods for dopamine
show similar LOQs to our method, respectively, 0.039 and
0.065 nmol/L versus 0.020 nmol/L for our method.26,27 The
authors from the first report used 25 μL of plasma, an
evaporation step, and a derivatization step for the amine
group.26 However, with this method, the LOQs for
epinephrine and norepinephrine were considerably higher
than for our method (0.10 and 0.39 nmol/L versus 0.03 and
0.010 nmol/L).26 The LOQ for epinephrine in particular was
not sufficient to measure endogenous epinephrine in human
plasma samples. The other report also used propionic
anhydride for the derivatization of dopamine but performed
the derivatization after the SPE step.27 For 3-methoxytyramine,
two earlier reports state LOQs for 3-methoxytyramine close to
our LOQ of 0.010 nmol/L, respectively 0.0375 and 0.024
nmol/L.28,29 However, these methods used 3−18 times more
plasma as well as high-end, more sensitive triple-quadrupole
mass spectrometers compared with our lower end, less
sensitive triple-quadrupole mass spectrometer. Another
advantage of our method is that we only use 50 μL of plasma;
so less blood needs to be taken from the patient or from
biobanks. Figure 4 displays chromatograms obtained from a
healthy volunteer, a patient with pheochromocytoma, and a
patient with head and neck paraganglioma. Chromatographic
selectivity was achieved on a phenyl-hexyl column, which
baseline separates the analytes, except for metanephrine and
norepinephrinethese two analytes can be discriminated
based on their m/z transitions and did not show cross-talk.
The LC-MS/MS analyses show distinctive profiles for the
healthy volunteer and the two patients (each chromatogram is
normalized to the same intensity for comparison). Figure 4B1/
B2 (patient with pheochromocytoma) shows increased
norepinephrine, epinephrine, normetanephrine, and meta-
nephrine concentrations compared with the healthy volunteer
(Figure 4A), whereas Figure 4C (patient with head and neck
paraganglioma) shows increased dopamine and 3-methoxytyr-
amine concentrations. These findings are in line with the
literature on pheochromocytoma and paraganglioma.3,30,31 No
analytical interferences were detected in the samples from the
antihypertensive medication study (β-blocker, thiazide diuretic,
or angiotensin-converting enzyme inhibitor).19 β-Blockers did
not interfere with the 3-methoxytyramine transitions in the
present study. This is in contrast to our previous HILIC LC-
MS/MS method, where we could not analyze 3-methoxytyr-
amine in patients using metoprolol because the β-blocker
interfered at the retention time of 3-methoxytyramine. In
addition to possible interference in conventional LC-MS/MS
assays, recent literature suggests that 3-O-methyldopa could
have a role in the diagnosis of neuroblastoma.5,32 We found
Figure 3. Proposed fragmentation scheme for each analyte: (A) L-
DOPA; (B) dopamine; (C) norepinephrine; (D) epinephrine; (E) 3-
methoxytyramine; (F) normetanephrine. Scheme for metanephrine is
shown in Figure S-10.
Figure 4. LC-MS/MS analyses of plasma from a healthy volunteer
(A), from one patient with pheochromocytoma (B1/B2), and from
one patient with HNPGL (C) in the SRM mode. Chromatograms
were normalized to the same intensity. (A) Calculated concentrations
in plasma were as follows: L-DOPA, 12 nmol/L; DA, 0.063 nmol/L;
NE, 2.3 nmol/L; E, 0.20 nmol/L; 3-MT, 0.010 nmol/L; NMN, 0.47
nmol/L; MN, 0.16 nmol/L. Calculated concentrations in plasma were
(for B and C, respectively) as follows: L-DOPA, 38 and 11 nmol/L;
DA, 0.26 and 1.3 nmol/L; NE, 5.2 and 5.9 nmol/L; E, 5.4 and 0.14
nmol/L; 3-MT, 0.033 and 0.22 nmol/L; NMN, 2.5 and 0.67 nmol/L;
MN, 5.2 and 0.084 nmol/L. Abbreviations: DA, dopamine; NE,
norepinephrine; E, epinephrine; 3-MT, 3-methoxytyramine; NMN,
normetanephrine; MN, metanephrine; HNPGL, head and neck
paraganglioma.
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that 3-O-methyldopa was easily incorporated in the assay and
did not interfere with other transitions. To validate the
accuracy of our new method, samples from the quality
assurance program for plasma-free metanephrines of the
Royal College of Pathologists of Australasia (RCPA) were
analyzed.33 Six samples, between January and March 2019,
were analyzed. They revealed excellent agreement with target
values reported by the RCPA Quality Assurance Program.
Errors ranged from −8.3% to 4% for 3-methoxytyramine, from
−12% to 3.7% for normetanephrine, and from −6.6% to 6.5%
for metanephrine (Table S-4).
Method Comparison. The LC-MS/MS method for
analyzing plasma norepinephrine and epinephrine was
compared with the HPLC-ECD assay routinely used in our
laboratory.17 Passing and Bablok regression demonstrated no
proportional or systematic bias for norepinephrine and a
systematic bias of −0.11 nmol/L for epinephrine (Figure S-9).
Epinephrine may have shown systematic bias because the
HPLC-ECD method uses a one-point calibration and a
structural analog as an internal standard (dihydroxybenzyl-
amine). Passing and Bablok regression revealed excellent
agreement for 3-methoxytyramine, normetanephrine, and
metanephrine with our previously reported HILIC-MS/MS
method (Figure S-9).15 For 3-methoxytyramine, several plasma
samples had to be excluded as 3-MT concentrations were
below the HILIC LC-MS/MS LOQ of 0.06 nmol/L and β-
blockers interfered with the HILIC LC-MS/MS method, as
previously mentioned. There was a proportional bias for
normetanephrine of 5% (95% CI 1.03−1.11) and for
metanephrine of 9% (95% CI 1.05−1.12) but not for 3-
methoxytyramine (2%; 95% CI 0.94−1.12). L-DOPA and
dopamine data could not be compared because our HPLC-
ECD method could not reliably detect endogenous levels of
these markers in plasma.
Reference Intervals. Reference intervals for all com-
pounds were established in the supine position. Whether blood
samples are collected with the patients in a sitting or supine
position has a significant influence, particularly on norepi-
nephrine and normetanephrine.34 Blood sampling in the
supine position is recommended by the clinical practice
guideline for pheochromocytoma and paraganglioma of the
Endocrine Society.35
Reference intervals were as follows: L-DOPA, 5.0−34 nmol/
L; dopamine, 0.024−0.18 nmol/L; norepinephrine, 0.68−4.0
nmol/L; epinephrine, 0.029−0.32 nmol/L; 3-methoxytyr-
amine, <0.036 nmol/L; normetanephrine, 0.17−0.79 nmol/
L; metanephrine, 0.068−0.28 nmol/L. Our reference intervals
were comparable to previously reported intervals for plasma
collected in a supine position.36,37
■ CONCLUSIONS
We describe a straightforward direct-matrix derivatization
procedure that is an improvement on all existing methods
for quantitation of plasma metanephrines and catecholamines
and that allows simultaneous mass spectrometric analysis of
plasma L-DOPA, catecholamines, and metanephrines for the
first time. The assay complies with international guidelines on
the validation of clinical assays. This study proves that
catecholamines and metanephrines can be propionylated
directly in plasma, which greatly improves their detection by
mass spectrometry. This increase in sensitivity is probably
related to the increased lipophilicity of the derivatives and
subsequent increase in ionization efficiency.21,38 Furthermore,
the method is highly automated, which reduces possible
human errors. It can be improved even more by converting the
liquid chromatography method to ultraperformance liquid
chromatography. This combination of profiling and enhanced
sensitivity represents a considerable improvement and may
open new possibilities for research on catecholamine
metabolism.
The low plasma volume needed for simultaneous analysis of
plasma L-DOPA, catecholamines, and metanephrines preserves
precious biobanked samples and is suitable for advanced
diagnostic applications that may open new avenues for
microsampling. This may improve the diagnosis of neuro-
blastoma in pediatric patients, as other methods are hindered
by their need for large sample volumes. Furthermore, the
method may have other preclinical research applications, such
as small animal studies, in vivo microdialysis, and cell culture
studies.
In conclusion, we present the first method for simultaneous
analysis of L-DOPA, catecholamines, and metanephrines that
uses direct-matrix derivatization in combination with online
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